Product Description
an antibacterial drug candidate (Sourced from: https://pubs.acs.org/doi/abs/10.1021/acs.oprd.0c00029)
Mechanisms of Action: MRSA Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01275781 |
D2690C00009 | P1 |
Withdrawn |
Healthy Volunteers |
2011-02-01 |
2019-03-19 |
Treatments |
|
NCT01064388 |
D2690C00002 | P1 |
Completed |
Healthy Volunteers |
2010-08-01 |
2019-03-19 |
Treatments |
|
NCT01114152 |
D2690C00003 | P1 |
Completed |
Healthy Volunteers |
2010-07-01 |
2019-03-19 |
||
NCT01124760 |
D2690C00008 | P1 |
Completed |
Healthy Volunteers |
2010-07-01 |
2019-03-19 |
Treatments |
|
NCT01154621 |
D2690C00007 | P1 |
Completed |
Healthy Volunteers |
2010-07-01 |
2019-03-19 |
||
NCT01030224 |
D2690C00001 | P1 |
Completed |
Healthy Volunteers |
2010-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|